What is Cellecta?
Cellecta, Inc. operates at the intersection of genomics and therapeutic development, providing a comprehensive suite of CRISPR and RNAi libraries alongside expert services for functional screening, cell engineering, and bioinformatics analysis. The company empowers researchers, primarily in the pharmaceutical and biotechnology industries, to accelerate the identification and validation of potential drug targets and biomarkers. By offering customizable solutions and robust analytical support, Cellecta facilitates a deeper understanding of genetic mechanisms crucial for advancing novel medical treatments.
How much funding has Cellecta raised?
Cellecta has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Cellecta?
The substantial backing indicated by the $350K and the context of a 'large-scale late-stage funding' round suggest Cellecta is poised for significant expansion and market penetration. This capital infusion is likely to fuel further development of their genomic technologies, enhance service offerings, and broaden their client base. Strategic partnerships and continued innovation in drug discovery tools will be key as Cellecta aims to solidify its role as a leader in enabling precision medicine and accelerating the drug development pipeline.
See full Cellecta company page
